Calidi Biotherapeutics Q2 EPS $(2.94) Down From $(1.99) YoY
Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(2.94) per share. This is a 47.74 percent decrease over losses of $(1.99) per share from the same period last year.
Stocks · News reference
Calidi Biotherapeutics Receives Pre-IND Regulatory Feedback From FDA Providing Alignment, Clarity On IND-Enabling Preclinical Plans And Clinical Strategy For CLD-401 Prior To Advancing Drug Candidate Into Phase 1 Clinical Studies
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Calidi Biotherapeutics Presents New Data On CLD-401 Program That It Expects To Enter Clinic In Q1 Of 2027 And In Situ T-Cell Engager Program, At 2026 AACR D3 Conference
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, presented on
Why Crown Holdings Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Crown Holdings Inc (CCK) stock gained 16.4% in pre-market trading after reporting strong Q2 results and raising its FY26 EPS guidance. Other gaining stocks include SLGB, HIHO, WNW, CHNR, RDGT, ULBI, GLMD, SMTK, and PRTA while LBGJ is down 45.1%.
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
Calidi Biotherapeutics announced a 1-for-16 reverse stock split effective July 31, 2026, approved by stockholders on June 12, 2026. The company aims to optimize market dynamics and broaden investor appeal. Every 16 pre-split shares will consolidate into one share, with fractional shares rounded up to the nearest whole share.